Evidence map›Paper›PMID 31492201›Full record

ArticleCritical care (London, England)2019

Impact of species and antibiotic therapy of enterococcal peritonitis on 30-day mortality in critical care-an analysis of the OUTCOMEREA database.

Anne-Cécile Morvan, Baptiste Hengy, Maïté Garrouste-Orgeas, Stéphane Ruckly, Jean-Marie Forel, Laurent Argaud, Thomas Rimmelé, Jean-Pierre Bedos, Elie Azoulay, Claire Dupuis and 4 more

Open access · goldAbstract read
In one paragraph

Article in Critical care (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Review
  5. Article
  6. Article
  7. Observational
  8. Review
  9. Review
  10. Article
  11. From the Friend to the Foe-International journal of molecular sciences · 2024
    Review
  12. Article
  13. Optimized Treatment of Nosocomial Peritonitis.Antibiotics (Basel, Switzerland) · 2023
    Review
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Review
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Anne-Cécile MorvanDepartment of Anesthesiology and Critical Care Medicine, Hospices Civils de Lyon, Edouard Herriot Teaching Hospital, 5 place d'Arsonval, 69003, Lyon, France. annececile.morvan@gmail.com.ORCID 0000-0003-3945-5515
Baptiste HengyDepartment of Anesthesiology and Critical Care Medicine, Hospices Civils de Lyon, Edouard Herriot Teaching Hospital, 5 place d'Arsonval, 69003, Lyon, France.
Maïté Garrouste-OrgeasPolyvalent ICU, St Joseph Hospital, Paris, France.
Stéphane RucklyUMR 1137 - IAME Team 5 - DeSCID: Decision Sciences in Infectious Diseases, Control and Care INSERM Paris Diderot University, Sorbonne Paris Cité, Paris, France.
Jean-Marie ForelMedical ICU, Respiratory Distress and Severe Infections, Nord Hospital, URMITE CNRS-UMR 6236, Aix-Marseille University, AP-HM, Marseille, France.
Laurent ArgaudMedical ICU, Hospices Civils de Lyon, Edouard Herriot Teaching Hospital, Lyon, France.
Thomas RimmeléDepartment of Anesthesiology and Critical Care Medicine, Hospices Civils de Lyon, Edouard Herriot Teaching Hospital, 5 place d'Arsonval, 69003, Lyon, France.
Jean-Pierre BedosIntensive Care Department, GHT Sud Yvelines, Centre Hospitalier de Versailles - Site André Mignot, Le Chesnay, Cedex, France.
Elie AzoulayMedical ICU, APHP, Saint-Louis Hospital, ECSTRA Team, and Clinical Epidemiology, UMR 1153 (Center of Epidemiology and Biostatistics, Sorbonne Paris Cité, CRESS), INSERM, Paris Diderot Sorbonne University, Paris, France.
Claire DupuisMedical and Infectious Diseases ICU, Bichat University Hospital, AP-HP, Paris, France.
Bruno MourvillierMedical and Infectious Diseases ICU, Bichat University Hospital, AP-HP, Paris, France.
Carole SchwebelMedical ICU, Albert Michallon Hospital, Grenoble 1 University, Grenoble, France.
Jean-François TimsitMedical and Infectious Diseases ICU, Bichat University Hospital, AP-HP, Paris, France.
OUTCOMEREA study group
Hospices Civils de Lyon · FRAssistance Publique – Hôpitaux de Paris · FRInserm · FRCentre Hospitalier Universitaire de Grenoble · FRCentre National de la Recherche Scientifique · FRHôpital Albert Michallon · FRHôpital André Mignot · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEnterococcus species are associated with an increased morbidity in intraabdominal infections (IAI). However, their impact on mortality remains uncertain. Moreover, the influence on outcome of the appropriate or inappropriate status of initial antimicrobial therapy (IAT) is subjected to debate, except in septic shock. The aim of our study was to evaluate whether an IAT that did not cover Enterococcus spp. was associated with 30-day mortality in ICU patients presenting with IAI growing with Enterococcus spp. MATERIAL AND

methodsRetrospective analysis of French database OutcomeRea from 1997 to 2016. We included all patients with IAI with a peritoneal sample growing with Enterococcus. Primary endpoint was 30-day mortality.

resultsOf the 1017 patients with IAI, 76 (8%) patients were included. Thirty-day mortality in patients with inadequate IAT against Enterococcus was higher (7/18 (39%) vs 10/58 (17%), p = 0.05); however, the incidence of postoperative complications was similar. Presence of Enterococcus spp. other than E. faecalis alone was associated with a significantly higher mortality, even greater when IAT was inadequate. Main risk factors for having an Enterococcus other than E. faecalis alone were as follows: SAPS score on day 0, ICU-acquired IAI, and antimicrobial therapy within 3 months prior to IAI especially with third-generation cephalosporins. Univariate analysis found a higher hazard ratio of death with an Enterococcus other than E. faecalis alone that had an inadequate IAT (HR = 4.4 [1.3-15.3], p = 0.019) versus an adequate IAT (HR = 3.1 [1.0-10.0], p = 0.053). However, after adjusting for confounders (i.e., SAPS II and septic shock at IAI diagnosis, ICU-acquired peritonitis, and adequacy of IAT for other germs), the impact of the adequacy of IAT was no longer significant in multivariate analysis. Septic shock at diagnosis and ICU-acquired IAI were prognostic factors.

conclusionAn IAT which does not cover Enterococcus is associated with an increased 30-day mortality in ICU patients presenting with an IAI growing with Enterococcus, especially when it is not an E. faecalis alone. It seems reasonable to use an IAT active against Enterococcus in severe postoperative ICU-acquired IAI, especially when a third-generation cephalosporin has been used within 3 months.

Indexed as

AgedAnti-Bacterial AgentsChi-Square DistributionCritical CareEnterococcaceaeFemaleHumansIncidenceMaleMiddle AgedMortalityPeritonitisProportional Hazards ModelsRetrospective StudiesRisk FactorsStatistics, NonparametricAnti-Bacterial AgentsAntibiotic therapyEnterococcus spp.Intensive careIntraabdominal infectionsMortality

Identifiers

PMID31492201
PMCPMC6731585
OpenAlexW2972139329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.